Member Article

Interserve to work on £38 million National Biologics Centre

The North East arm of Interserve Construction Ltd have been selected to design and build the forthcoming £38 million National Biologics Centre, to be based in Darlington.

Interserve, who operate from Wilton, were appointed by The Centre for Process Innovation (CPI) to build the major open access facility that will help companies to develop, prove, prototype and commercialise new biologic products.

The Central Park centre aims to foster the UK pharmaceutical industry and supply chain in the rapidly growing biologics market and increase the prospect for products developed in this country.

Work is expected to start on the National Biologics Centre in April, to be completed by the end of March 2015.

The facility will provide laboratory space, pilot plant areas for process, analytical and technology development; clean rooms for GMP process and equipment providing and testing areas.

Training and conferencing facilities will also be incorporated.

CPI’s Dr Chris Dowle, director of the NBMC said “This contract will create new jobs for the region helping to boost the local economy as well as delivering a state of art centre to boost the competitiveness of the UK biologics sector”

David Flewker, regional director at Interserve said “Interserve, the international support services and construction group are delighted to be involved in the delivery of the National Biologics Manufacturing Centre.

“We have operated in the Tees Valley for nearly 60 years and this strategically important facility will enhance the reputation and status of the region as a world leader in this field.”

This was posted in Bdaily's Members' News section by Tom Keighley .